'Vitamins, Minerals and Supplements Market Assessment 2007' Reveals the VMS Market Grew by Only 0.4% in Value Terms in the 12 Months Ending August 2007
DUBLIN, Ireland--(Business Wire)--Research and Markets
(http://www.researchandmarkets.com/reports/c81270) has announced the
addition of "Vitamins, Minerals and Supplements Market Assessment
2007" to their offering.
The market for vitamins, minerals and supplements (VMS) grew by
only 0.4% in value terms in the 12 months ending August 2007. This
follows a history of market declines in 2001 and 2002, significant
growth in 2003 and 2004, but only marginal growth since then.
Virtually all growth has been in supplements, with vitamin products
accounting for just over 30% of the market in 2006/2007 by value, and
minerals and supplements representing nearly 70%. The VMS market is
forecast to grow only slowly over the next 5 years (to 2011/2012).
The ageing population profile of the UK will continue to benefit
VMS products sales, since, in general, consumption rises with age.
Manufacturers are increasingly producing supplements more specifically
targeted at age-related conditions, such as those affecting the heart,
the brain, the eyes and joints; the most successful products in recent
years have been glucosamines and omega-3 fish oils. In addition, there
is an overall greater interest shown in a healthier lifestyle, and
greater affluence among the older population than previously.
However, the market has been held back by the periodic publication
of research studies concluding that many of those taking VMS products
do so unnecessarily. It is, nonetheless, agreed that certain groups of
people do benefit from their consumption. There is no scientific proof
that supplementing the diet generally with extra vitamins or minerals
is beneficial, and there could be a danger of overconsumption.
In addition, the VMS market has been under threat since 2002 from
the EU's Food Supplement Directive (FSD), which is charged with
setting maximum recommended daily consumption levels for all VMS
formulations, and organising manufacturers to provide data in order to
gain safety approvals for their VMS products. Some products already
appear on the FSD's `positive list', but many others are as yet not
approved, and will therefore not be able to be sold after 31st
December 2009 (unless they obtain approval). This whole initiative has
proved to be a substantial undertaking, and -- although it was
scheduled for completion in 2005 -- remains still largely under
discussion.
Multivitamins and fish oils continue to represent the largest
segments of the VMS market, followed by single vitamins and, now,
glucosamines. Sales in several sectors of the market are declining,
although those of multivitamins, single vitamins and minerals appear
to have stabilised.
Chemist and druggist shops are still estimated to account for the
largest, and now stable, share of sales of VMS products -- headed by
Alliance Boots. Earlier, they had been losing share to grocery
multiples, after the removal of resale price maintenance (RPM) on
over-the-counter (OTC) medicines in 2001. The share held by grocery
multiples also appears to have now stabilised, led by Tesco.
Health-food shops still account for a large but slowly declining share
of sales, dominated by Holland & Barrett, while a small but growing
market share is held by direct-selling channels such as mail order and
the Internet.
Seven Seas is by far the largest manufacturer of branded VMS
products, with a very wide range covering most segments. Bayer, which
has acquired Roche's retail VMS business, lies in second place within
brands, specialising in vitamin products. Many other smaller suppliers
of brands specialise in particular segments of the market. However, a
large market share within VMS is held by retailers' own-label
products, notably those of Holland & Barrett and Alliance Boots.
There have been a number of changes among manufacturers in the VMS
market in recent years. Apart from Bayer's acquisition of Roche's
retail vitamins business, Galenica has acquired Potters Herbal
Medicines -- which has then bought certain VMS products from Chefaro
and Boehringer Ingelheim, and also the manufacturer Equazen; William
Ransom has acquired Health Perception; Solgar has been bought by NBTY;
and Efamol has been acquired by Wassen.
Executive Summary
1. Introduction
2. Strategic Overview
3. Multivitamins
4. Single Vitamins
5. Fish Oils
6. Evening Primrose and Starflower Oils
7. Minerals and Other Supplements
8. Advertising and Promotion
9. Distribution
10. An International Perspective
11. PEST Analysis
12. Consumer Dynamics
13. Company Profiles
14. The Future
15. Further Sources
Companies mentioned:
- Bayer Consumer Care -- Bayer PLC
- BHM Health Group Ltd
- Boehringer Ingelheim Ltd
- Chefaro UK Ltd
- Efamol Ltd
- Equazen UK Ltd
- Ernest Jackson & Co Ltd
- Health Perception (UK) Ltd
- Klosterfrau Healthcare (formerly Lichtwer Pharma AG)
- Potters Herbal Medicines -- Potters Ltd
- Seven Seas Ltd
- Solgar Vitamin & Herb
- Vitabiotics Ltd
- Wassen International Ltd
- Wyeth Consumer Healthcare
- Cultech Ltd
- DCC Health & Beauty Solutions Ltd (formerly DCC Nutraceuticals
Ltd)
- Nature's Aid Ltd
- Pharma Nord
- Quest Vitamins Ltd
- Alliance Boots Ltd
- Holland & Barrett Retail Ltd
- Superdrug Stores PLC
- Tesco Stores Ltd
For more information visit
http://www.researchandmarkets.com/reports/c81270
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
Copyright Business Wire 2008
